Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2010

View Archived Issues

Recombinant polypeptide can extend half-life of proteins and peptides

Penwest initiates phase IIa trial of A-0001 in A3243G mitochondrial DNA point mutation

Detection of label-free biomarkers in whole blood samples reported

HSV-2 suppression with acyclovir does not reduce risk for HIV-1 transmission

Combined targeting of beta/gamma-secretase shows promise as new AD therapy

New therapeutic target found in NS4B protein of hepatitis C virus

Ablynx selected anti-CXCR4 Nanobody ALX-0651 for preclinical development

FDA approves SPA for phase III trial of HyperAcute immunotherapy in pancreatic cancer

Excelimmune receives Series B funding for development of Staphguard

Anacor regains worldwide rights to AN-2690 from Merck

Circassia reports phase II results with ragweed allergy T-cell vaccine

Synta reports STA-9090 results showing potent in vitro and in vivo activity in AML

FDA extends Horizant PDUFA date

Cerus reports outcome of phase I trial of Intercept red blood cells

PolyMedix reports milestones scheduled for 2010

Tyrogenex presents protein kinase inhibitors for cancer therapy

Theracos identifies novel sodium/glucose cotransporter inhibitors

New MR antagonists discovered at Bayer Schering Pharma

S1P1 receptor agonists discovered by GlaxoSmithKline

Janus kinase inhibitors identified by Merck & Co.

Genta initiates phase II tesetaxel trial in patients with advanced melanoma

YM BioSciences presents CYT-387 and CYT-997 data

Euthymics Bioscience signs letter of intent for acquisition of DOV

KineMed broadens collaboration with Bristol-Myers Squibb

Proteonomix forms wholly owned subsidiary PRTMI for stem cell research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...